Idorsia | Portfolio overview

Compound	Mechanism of action	Target indication	Status	More Information

QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, and France; approved throughout the EU	Investor webcast
TRYVIO™ (aprocitentan)	Dual endothelin receptor antagonist	Systemic hypertension in combination with other antihypertensive drugs	Approved in the US, product availability planned for Q4 2024	Investor webcast
JERAYGO™ (aprocitentan)	Dual endothelin receptor antagonist	Resistant hypertension in combination with other antihypertensive drugs	Approved in the EU. Marketing authorization applications for the UK, Canada, and Switzerland in preparation	Investor webcast
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met, open-label extension study ongoing Phase 3 focused on renal function in preparation
ACT-1004-1239	ACKR3/CXCR7 antagonist	Demyelinating diseases including multiple sclerosis	Phase 2 in preparation
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete
ACT-777991	CXCR3 antagonist	Recent-onset Type 1 diabetes	Phase 1 complete
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1
IDOR-1134-2831	Synthetic glycan vaccine	Clostridium difficile infection	Phase 1 initiating

Compound	Mechanism of action	Target indication	Partner: Terms	Status

Daridorexant	Dual orexin receptor antagonist	Insomnia	Nxera Pharma: license to develop and commercialize for Asia-Pacific region (excluding China)	NDA submitted in Japan
Daridorexant	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	Phase 3 successful, NDA planned for H2 2024
Selatogrel	P2Y₁₂ inhibitor	Suspected acute myocardial infarction	Viatris: worldwide development and commercialization rights	Phase 3 “SOS-AMI” program ongoing
Cenerimod	S1P₁ receptor modulator	Systemic lupus erythematosus	Viatris: worldwide development and commercialization rights (excluding Japan, South Korea, and certain countries in the Asia-Pacific region)	Phase 3 “OPUS” program ongoing
Daridorexant	Dual orexin receptor antagonist	Posttraumatic stress disorder (PTSD)	US Department of Defense (DOD): Idorsia supports a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	Phase 2
ACT-709478/ NBI-827104	T-type calcium channel blocker	Epileptic encephalopathy with continuous spike-and-wave during sleep (CSCW)	Neurocrine Biosciences: global license to develop and commercialize	Phase 2 OLE study ongoing
ACT-1002-4391	EP₂ / EP₄ receptor antagonist	Immuno-oncology	Owkin: global license to develop and commercialize	Phase 1 in preparation

Bench to bedside